First line vs delayed transplantation in myeloma: Certainties and controversies

Table 3 Major studies of delayed autologous stem cell transplantation (for randomised trials only data regarding delayed autologous stem cell transplantation are reported)

Ref.	Publication’s year	Patients n	Type of trial	Median interval between diagnosis or first ASCT and delayed ASCT	Previous ASCT	ORR (%)	PFS (mo)	OS (mo)
Cook et al[49]	2011	106	Retrospective	19 mo (relapse from first transplant)	Yes	63%	NR	37
Jimenez-Zepeda et al[51]	2012	81	Retrospective	39 mo (relapse from first transplant)	Yes	97.4%	16.43	53
Sellner et al[44]	2013	200	Retrospective	NR	Yes	80.4%	15.2	43.2
Cook et al[46]	2014	89	Prospective	2.7 yr	Yes	83%	19	80.3% at 3 yr
Gertz et al[29]	2000	64	Prospective	NR	No	97%	11.4	19.6
Michaelis et al[45]	2013	187	Retrospective	32 mo	Yes	68%	5% at 5 yr	29% at 5 yr
Shah et al[68]	2012	44	Retrospective	30 mo	Yes	90%	12.3	31.7
Kumar et al[48]	2012	112	Prospective	> 12 mo	No	32% (≥ VGPR)	16 (TTP)	73.4% at 4 yr
Dunavin et al[47]	2013	65	Retrospective	17.7 mo	No	NR	23 (TTP)	63% at 5 yr

VGPR: Very good partial response; TTP: Time to progression; PFS: Progression free survival; ASCT: Autologous stem cell transplant; OS: Overall survival; NR: Not reported; ORR: Overall response rate.